288 results
Categories
Human Remove Human filter
-
List item
Withdrawn application: Sitoiganap
autologous glioma tumor cell lysates (inactivated), allogeneic glioma tumor cell lysates (inactivated), allogeneic glioma tumor cells (inactivated), autologous glioma tumor cells (inactivated), date of withdrawal: 02/05/2022, Initial authorisation, Last updated: 17/06/2022Sitoiganap: Withdrawn application … tumor cells (inactivated) Overview Epitopoietic Research Corporation-Belgium … Corporation-Belgium (E.R.C.) withdrew its application for a The approval to market … -
List item
Withdrawn application: Aliqopa
copanlisib, date of withdrawal: 20/12/2021, Initial authorisation, Last updated: 10/02/2023Aliqopa: Withdrawn application … copanlisib Overview Bayer AG withdrew its application for a The approval to market … The company withdrew the application on 20 December 2021. What … -
List item
Withdrawn application: Imbarkyd
bardoxolone methyl, date of withdrawal: 09/11/2022, Initial authorisation, Last updated: 07/02/2023Imbarkyd: Withdrawn application … bardoxolone methyl Overview Reata Ireland Limited withdrew … Ireland Limited withdrew its application for a The approval to market … -
List item
Withdrawn application: Garsun (new)
artesunate, date of withdrawal: 08/12/2022, Initial authorisation, Last updated: 01/03/2023Garsun: Withdrawn application … B & O Pharm withdrew its application for a The approval to market … The company withdrew the application on 8 December 2022. Expand … -
List item
Withdrawn application: Hervelous
trastuzumab, date of withdrawal: 14/09/2022, Initial authorisation, Last updated: 13/12/2022Hervelous: Withdrawn application … trastuzumab Overview Prestige Biopharma Belgium … Belgium BVBA withdrew its application for a The approval to market … -
List item
Withdrawn application: Tuznue
trastuzumab, date of withdrawal: 14/09/2022, Initial authorisation, Last updated: 13/12/2022Tuznue: Withdrawn application … trastuzumab Overview Prestige Biopharma Belgium … Belgium BVBA withdrew its application for a The approval to market … -
List item
Withdrawn application: HemAryo
eptacog alfa (activated), date of withdrawal: 06/05/2022, Initial authorisation, Last updated: 27/09/2022HemAryo: Withdrawn application … eptacog alfa (activated) Overview UGA Biopharma withdrew its application for a The approval to market … The company withdrew the application on 6 May 2022. What is HemAryo … -
List item
Withdrawn application: Flynpovi
eflornithine, sulindac, date of withdrawal: 12/10/2021, Initial authorisation, Last updated: 07/12/2021Flynpovi: Withdrawn application … eflornithine sulindac Overview Cancer Prevention Pharma … Ireland) Limited withdrew its application for a The approval to market … -
List item
Withdrawn application: Abylqis
arachis hypogaea extract, date of withdrawal: 17/12/2021, Initial authorisation, Last updated: 23/11/2022Abylqis: Withdrawn application … arachis hypogaea extract Overview DBV Technologies withdrew … Technologies withdrew its application for a The approval to market … -
List item
Withdrawn application: Ilaris (updated)
canakinumab, date of withdrawal: 26/10/2022, Post-authorisation, Last updated: 23/02/2023Ilaris: Withdrawn application … canakinumab Overview Novartis withdrew its application for the use of Ilaris in … The company withdrew the application on 26 October 2022. What … -
List item
Withdrawn application: Miplyffa
arimoclomol, date of withdrawal: 22/03/2022, Initial authorisation, Last updated: 08/02/2023Miplyffa : Withdrawn application … company present to support its application? The company provided results … including miglustat where applicable). Effectiveness was measured … -
List item
Withdrawn application: Gavreto
pralsetinib, date of withdrawal: 03/11/2022, Post-authorisation, Last updated: 02/02/2023Gavreto: Withdrawn application … pralsetinib Overview Roche Registration GmbH withdrew … Registration GmbH withdrew its application for the use of Gavreto in … -
List item
Withdrawn application: Febseltiq
infigratinib, date of withdrawal: 11/10/2022, Initial authorisation, Last updated: 30/01/2023Febseltiq: Withdrawn application … infigratinib Overview Helsinn Birex Pharmaceuticals … Pharmaceuticals Ltd withdrew its application for a The approval to market … -
List item
Withdrawn application: Exkivity
mobocertinib, date of withdrawal: 20/07/2022, Initial authorisation, Last updated: 24/11/2022Exkivity: Withdrawn application … mobocertinib Overview Takeda Pharma A/S withdrew … Takeda Pharma A/S withdrew its application for a The approval of a medicine … -
List item
Withdrawn application: Zektayos - Hepjuvo
obeticholic acid, date of withdrawal: 09/12/2021, Initial authorisation, Last updated: 08/04/2022Zektayos - Hepjuvo: Withdrawn application … obeticholic acid Overview Intercept Pharma International … International Limited withdrew its application for a The approval to market … -
List item
Withdrawn application: Sevsury
surufatinib, date of withdrawal: 01/08/2022, Initial authorisation, Last updated: 16/11/2022Sevsury: Withdrawn application … surufatinib Overview Hutchmed Europe B.V. withdrew … Europe B.V. withdrew its application for a The approval to market … -
List item
Withdrawn application: Dimherity
dimethyl fumarate, date of withdrawal: 22/02/2022, Initial authorisation, Last updated: 03/11/2022Dimherity: Withdrawn application … dimethyl fumarate Overview Sandoz GmbH withdrew its application for a The approval to market … The company withdrew the application on 22 February 2022. What … -
List item
Withdrawn application: Aduhelm
aducanumab, date of withdrawal: 20/04/2022, Initial authorisation, Last updated: 01/08/2022Aduhelm: Withdrawn application … aducanumab Overview Biogen Netherlands B.V. withdrew … Netherlands B.V. withdrew its application for a The approval to market … -
List item
Withdrawn application: Neffy
epinephrine, date of withdrawal: 04/04/2022, Initial authorisation, Last updated: 20/05/2022Neffy: Withdrawn application … epinephrine Overview ARS Pharmaceuticals IRL … IRL, Limited withdrew its application for a The approval to market … -
List item
Withdrawn application: Topotecan SUN
topotecan, date of withdrawal: 03/01/2011, Initial authorisation, Last updated: 23/02/2011Topotecan SUN: Withdrawn application … topotecan Overview On 3 January 2011, Sun Pharmaceutical … it wishes to withdraw its application for a marketing authorisation … -
List item
Withdrawn application: Orepaxam
treprostinil diolamine, date of withdrawal: 11/10/2022, Initial authorisation, Last updated: 11/11/2022Orepaxam: Withdrawn application … Internacional S.A. withdrew its application for a The approval to market … The company withdrew the application on 11 October 2022. Expand … -
List item
Withdrawn application: Pioglitazone ratio
pioglitazone, date of withdrawal: 03/02/2012, Initial authorisation, Last updated: 30/04/2012Pioglitazone ratio: Withdrawn application … pioglitazone Overview On 3 February 2012, ratiopharm … it wishes to withdraw its application for a marketing authorisation … -
List item
Withdrawn application: Pioglitazone ratiopharm
pioglitazone, date of withdrawal: 03/02/2012, Initial authorisation, Last updated: 30/04/2012Pioglitazone ratiopharm: Withdrawn application … pioglitazone Overview On 3 February 2012, ratiopharm … it wishes to withdraw its application for a marketing authorisation … -
List item
Withdrawn application: Repaglinide Sun
repaglinide, date of withdrawal: 25/03/2010, Initial authorisation, Last updated: 15/05/2010Repaglinide Sun: Withdrawn application … repaglinide Overview On 23 March 2010, Sun Pharmaceutical … it wished to withdraw its application for a marketing authorisation … -
List item
Withdrawn application: Docetaxel Mylan
docetaxel, date of withdrawal: 08/03/2010, Initial authorisation, Last updated: 26/03/2010Docetaxel Mylan: Withdrawn application … docetaxel Overview On 8 March 2010, Mylan S.A.S … it wishes to withdraw its application for a marketing authorisation …